I am a virologist and structural biologist with over a decade of experience studying innate immune signaling pathways, host–pathogen co-evolution, and the development of next-generation vaccines. My research integrates virology, structural biology, molecular immunology, and biochemical methodologies to uncover mechanisms of antiviral defense—particularly those related to poxviruses—and translate these discoveries into novel vaccine strategies. My work has significantly advanced our understanding of the processes underlying viral entry and fusion, PKR-mediated antiviral responses, and viral regulation of NF-κB signaling. I have authored multiple first-author publications in leading journals such as PNAS and Trends in Immunology, and have contributed as a co-author on a collaborative Nature Microbiology study with researchers at Yale University. At the NIH, under the mentorship of Dr. Bernard Moss, a distinguished member of the U.S. National Academy of Sciences, I have driven innovative research leading to a preprint manuscript on bioRxiv that focuses on neutralizing antibodies targeting poxvirus entry proteins. Additionally, our collaborative efforts have resulted in two international patent applications aimed at advancing poxvirus-based vaccine technologies. With a steadfast commitment to scientific exploration and interdisciplinary collaboration, my goal is to lead cutting-edge research that bridges fundamental virology and translational biomedical science.